Table S1. Additional exclusions

Exclusion	Time period
Received any vaccine	30 days prior to enrolment
Planned to receive a vaccine	During the study between enrolment and the last study vaccination
Received immune globulins, blood, or blood-derived products	3 months prior to enrolment
Known or suspected congenital or acquired immunodeficiency	Any time
Received immunosuppressive therapy	6 months prior to enrolment
Received long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks)	3 months prior to enrolment
Systemic hypersensitivity to any of the vaccine components or life-threatening reaction to the trial vaccine or a vaccine containing any of the same substances	Any time
Guillain-Barré syndrome	Any time
Thrombocytopenia, which may be a contraindication for intramuscular vaccination, at the discretion of the investigator	Any time
Bleeding disorder, or receipt of anticoagulants contraindicating intramuscular vaccination	3 weeks prior to enrolment
Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized	At inclusion

involuntarily	
Serious adverse reactions to any influenza vaccine	Any time
Any other illness or disorder that might, in the investigator's opinion, affect the outcome of the study	At inclusion
Known seropositivity for human immunodeficiency virus, hepatitis B, or hepatitis C	Any time
Identified as a natural or adopted child of either the Investigator or an employee with direct involvement in the proposed study.	Any time